Vaderis, FDA

Vaderis erhĂ€lt FDA Fast Track Designation fĂŒr VAD044 zur Behandlung der hereditĂ€ren hĂ€morrhagischen Telangiektasie

Published on 08/07/2025 at 18:07 | prnewswire.co.uk

Vaderis Therapeutics AG Austria Belgium France Germany Italy Netherlands Spain Switzerland United Kingdom Maryland United States of America Canada Europe

View original content:https://www.prnewswire.com/news-releases/vaderis-erhalt-fda-fast-track-designation-fur-vad044-zur-behandlung-der-hereditaren-hamorrhagischen-telangiektasie-302307636.html

en | boerse | 67942967 |